JANUX THERAPEUTICS INC (JANX)
Sector: Health Care
2026 Annual Meeting Analysis
JANUX THERAPEUTICS INC · Meeting: June 11, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Class II Directors
Ms. Hernday joined the board in July 2024, which is less than 24 months before the meeting date, making her exempt from the stock performance trigger under policy; she also brings strong relevant biotech industry experience from senior roles at Seagen and Amgen.
Mr. Dobmeier joined the board in July 2024, which is less than 24 months before the meeting date, making him exempt from the stock performance trigger under policy; he brings extensive biotech executive and board experience from roles including CEO of Chinook Therapeutics and COO of Seagen.
Both Class II nominees — Natasha Hernday and Eric Dobmeier — joined the board in July 2024, fewer than 24 months before the June 2026 annual meeting, and are therefore exempt from the TSR underperformance trigger under policy. Both nominees have strong, relevant biotechnology industry credentials, no overboarding concerns, no independence issues, and the proxy discloses all directors met the 75% meeting attendance threshold in 2025. The vote determination is FOR both nominees.
Say on Pay
✗ AGAINSTCEO
David Campbell, Ph.D.
Total Comp
$13,506,231
Prior Support
97.9%%
The CEO received $13,506,231 in total compensation in 2025, the vast majority of which ($12,459,031) came from stock option awards granted in a single year — an unusually large award for a company with an $882 million market cap and a stock that has fallen 55% over the past year and returned -3.6% over three years, compared to a +60.7% gain for the XBI (SPDR S&P Biotech ETF) benchmark, a gap of -64.3 percentage points. This is a clear pay-for-performance disconnect: shareholders have experienced significant losses while above-benchmark incentive pay was delivered. Additionally, the company's own pay-versus-performance disclosure states that no financial performance measures are used to link executive compensation to company performance, meaning the equity grants effectively vest regardless of measurable financial outcomes — a structure the policy treats as fixed pay disguised as variable pay, warranting a NO vote.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$972,691
Non-Audit Fees
$3,600
The non-audit fees paid to Ernst & Young LLP in 2025 were just $3,600 (access to a research database) compared to audit fees of $972,691, representing less than 0.4% of audit fees — far below the 50% threshold that would raise independence concerns. Auditor tenure is not disclosed in the proxy, so the tenure trigger does not fire per policy. Ernst & Young is a Big 4 firm appropriate for a company of this size and complexity, and no material financial restatements are noted.
Overall Assessment
The 2026 Janux Therapeutics annual meeting presents three standard proposals: director elections, auditor ratification, and a say-on-pay advisory vote. Both director nominees are exempt from TSR scrutiny due to their recent appointment dates, and the auditor relationship is clean with negligible non-audit fees, resulting in FOR votes on those two items; however, the say-on-pay vote warrants an AGAINST determination due to a very large CEO compensation package that is misaligned with the company's significant stock underperformance relative to the XBI biotech benchmark, compounded by the company's own admission that no financial performance measures are used to link pay to results.
Compensation Peer Group
16 companies disclosed in 2026 proxy filing